Former Obama White House Health Reformer Nancy-Ann DeParle's Consonance Capital monetized Orsini Specialty Pharmacy by selling a stake to The Carlyle Group. Axios reported:
Orsini manages the handling and service requirements of costly and complex pharmaceuticals, with a particular focus on ultra rare drugs that oftentimes serve patient counts in the thousands.
Offerings include dispensing, distribution, reimbursement, case management services, among other personalized, therapy-specific services.
Carlyle did a press release on the deal. It did not mention the deal price or how much PPACA author DeParle personally profited.
Consonance Capital sold Enclara Healthcare, a hospice pharmacy provider and benefit manager to Humana in 2020. Humana's press release also failed to provide the purchase price or how much Nancy Ann DeParle profited.
Humana's Annual Report for FY 2020 revealed:
In the first quarter of 2020, we acquired privately held Enclara Healthcare, or Enclara, one of the nation’s largest hospice pharmacy and benefit management providers for cash consideration of approximately $709 million, net of cash received. This resulted in a purchase price allocation to goodwill of $517 million, other intangible assets of $240 million, and net tangible liabilities assumed of $13 million.
Nearly 73% of the purchase price went to goodwill. Since that time Humana decided to monetize its hospice and community care division. It's not clear if Enclara will go with Kindred Hospice when it is sold yet again.
President Obama knew his White House Health Reformer was a deal maker, who'd personally made a fortune prior to her appointment.
While in the role of White House Health Reformer DeParle received a residual private equity payout from a medical imaging company. The firm was never mentioned in any of her prior financial disclosures.
MQ Interholdings, LLC (share of proceeds of earn-out of 2007 sale of CCMP portfolio company)
Her capital gain from the sale of MedQuest, a medical imaging company, was $6,825.
Rest assured PPACA designer DeParle made massive profits on Consonance's flipping of Enclara and part of Orsini. This occurs while your medications become more unaffordable and less available.
